Brady Martz Wealth Solutions LLC Purchases New Shares in Pfizer Inc. (NYSE:PFE)

Brady Martz Wealth Solutions LLC bought a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 57,714 shares of the biopharmaceutical company's stock, valued at approximately $1,524,000.

A number of other hedge funds have also made changes to their positions in the stock. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the 4th quarter worth $26,000. Gladius Capital Management LP increased its holdings in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 38,015 shares during the last quarter. Quarry LP acquired a new stake in Pfizer during the second quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America bought a new position in Pfizer during the 3rd quarter worth approximately $35,000. Finally, Joseph Group Capital Management grew its position in shares of Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 771 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Price Performance

PFE stock traded down $0.19 during trading on Friday, hitting $26.30. The company had a trading volume of 35,146,711 shares, compared to its average volume of 35,869,448. The firm has a market capitalization of $149.06 billion, a price-to-earnings ratio of 35.55, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business has a 50 day moving average of $26.08 and a 200 day moving average of $27.99. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion during the quarter, compared to analysts' expectations of $14.92 billion. During the same period last year, the firm posted ($0.17) earnings per share. The business's revenue was up 31.2% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer's previous quarterly dividend of $0.42. Pfizer's payout ratio is currently 232.43%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on PFE. Bank of America restated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. StockNews.com lowered shares of Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Guggenheim decreased their target price on Pfizer from $35.00 to $33.00 and set a "buy" rating for the company in a research note on Wednesday, December 11th. Finally, Sanford C. Bernstein initiated coverage on Pfizer in a research report on Thursday, October 17th. They set a "market perform" rating and a $32.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and an average target price of $32.00.

Insider Activity

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the company's stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company's stock, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.06% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.